Abstract
1 Methodological reasons are discussed which make placebo-controlled trials on antidepressant drugs necessary.
2 The ethical problem of treating a sick patient with an inactive compound are shown to have an impact on the methodology of such trials.
3 Three double-blind placebo-controlled trials with nomifensine are reviewed; one in neurotic depression, one in psychotic depression and one in geriatric patients showing depressive symptoms.
4 In all three trials the effect of nomifensine has been shown to be superior to that of placebo.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
- Immich H., Eckmann F., Neumann H., Schäpperle O., Schwarz H., Tempel H. Grundlegende Probleme bei der Antidepressiva-Prüfung. Arzneimittelforschung. 1971 Apr;21(4):525–528. [PubMed] [Google Scholar]
- Immich H., Eckmann F., Neumann H., Schäpperle O., Schwarz H., Tempel H. Grundlegende Probleme bei der Antidepressiva-Prügung. Arzneimittelforschung. 1971 May;21(5):644–649. [PubMed] [Google Scholar]
- Plutchik R., Conte H., Lieberman M., Bakur M., Grossman J., Lehrman N. Reliability and validity of a scale for assessing the functioning of geriatric patients. J Am Geriatr Soc. 1970 Jun;18(6):491–500. doi: 10.1111/j.1532-5415.1970.tb01335.x. [DOI] [PubMed] [Google Scholar]